Hi Hoyland, your quote below is the creative loop hole I am surprised Nant has not capitalized on by running more of their cancer programs through Benitec.
"Also, the "grant" is a R&D tax incentive and so the more we spend on R&D, the more we can claim back." (non dilutive funding)
Why wouldn't Nant do a lot of R&D for cancer through Benitec where you would receive a tax credit & beneficial dollar exchange rate?
At the end of the day Nant's core focus is on cancer not AMD, OPMD or HBV.
I Agree we should partner OPMD with big pharma to get get more upfront non -dilutive capital and get some much needed creditability.
Jerel Banks is the chairman has a vested interest in making sure Benitec focuses on Car-t joint ventures to please his boss Patrick Soon.
Our partner Regen BioPharma, dCellVax Gene-Silenced Breast cancer immunotherapy is where we could allocate some of our opmd money to help develop dCellVax for a larger equity stake in the program.
- Forums
- ASX - By Stock
- BLT
- Ann: Interim Report 3 Months to 30 September 2017
Ann: Interim Report 3 Months to 30 September 2017, page-8
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online